27259326|t|Effect of Transcatheter Arterial Chemoembolization Combined with Argon-Helium Cryosurgery System on the Changes of NK Cells and T Cell Subsets in Peripheral Blood of Hepatocellular Carcinoma Patients
27259326|a|Hepatocellular carcinoma (HCC) is one of the most aggressive tumors in humans. T lymphocytes and natural killer (NK) cells are the body's first line of defense to prevent tumor cell growth. Previous studies have demonstrated that transcatheter arterial chemoembolization (TACE) combined with argon-helium cryosurgery system (AHCS) can effectively treat liver cancer. However, the mechanism of the treatment is unclear yet. In the current study, we investigated the effects of TACE combined with AHCS on the changes of T cell subsets and NK cells in peripheral blood of HCC. Our data show that alpha-fetoprotein (AFP) levels in peripheral blood were significantly up-regulated in HCC patients before treatment when compared with healthy people and reduced after TACE combined with AHCS treatment (P < 0.01). In addition, we found that CD4+ cells and NK cells decreased (P < 0.05) and CD8+ cells increased (P < 0.05) in HCC patients when compared with healthy people. After treatment, the CD4+ cells, CD4+ / CD8+ ratio, and NK cells were dramatically increased in HCC patients (P < 0.05). In contrast, CD8+ cells were significantly decreased (P < 0.05). TACE combined with AHCS treatment significantly prolonged 1- year survival rate of HCC patients and did not show significant side effects. Taken together, our data indicate that TACE combined with AHCS treatment improves patients ' immune system. It is a feasible and effective therapeutic method for HCC patients.
27259326	0	6	Effect	T080	C1280500
27259326	10	50	Transcatheter Arterial Chemoembolization	T061	C3888803
27259326	65	96	Argon-Helium Cryosurgery System	T061	C0010408
27259326	104	111	Changes	T169	C0392747
27259326	115	123	NK Cells	T025	C0022688
27259326	128	142	T Cell Subsets	T025	C0080202
27259326	146	162	Peripheral Blood	T031	C0229664
27259326	166	190	Hepatocellular Carcinoma	T191	C2239176
27259326	191	199	Patients	T101	C0030705
27259326	200	224	Hepatocellular carcinoma	T191	C2239176
27259326	226	229	HCC	T191	C2239176
27259326	250	260	aggressive	T080	C1550594
27259326	261	267	tumors	T191	C0027651
27259326	271	277	humans	T016	C0086418
27259326	279	292	T lymphocytes	T025	C0039194
27259326	297	311	natural killer	T025	C2709199
27259326	313	315	NK	T025	C2709199
27259326	317	322	cells	T025	C0007634
27259326	331	337	body's	T016	C0242821
27259326	352	359	defense	T042	C0520990
27259326	363	370	prevent	T080	C2700409
27259326	371	381	tumor cell	T025	C0597032
27259326	382	388	growth	T043	C0007595
27259326	390	406	Previous studies	T062	C2603343
27259326	430	470	transcatheter arterial chemoembolization	T061	C3888803
27259326	472	476	TACE	T061	C3888803
27259326	492	523	argon-helium cryosurgery system	T061	C0010408
27259326	525	529	AHCS	T061	C0010408
27259326	525	529	AHCS	T061	C0010408
27259326	535	546	effectively	T080	C1704419
27259326	547	552	treat	T061	C0087111
27259326	553	565	liver cancer	T191	C0345904
27259326	580	589	mechanism	T169	C0441712
27259326	597	606	treatment	T061	C0087111
27259326	610	617	unclear	T033	C3845108
27259326	638	643	study	T062	C2603343
27259326	648	660	investigated	T169	C1292732
27259326	665	675	effects of	T080	C1704420
27259326	676	680	TACE	T061	C3888803
27259326	695	699	AHCS	T061	C0010408
27259326	707	714	changes	T169	C0392747
27259326	718	732	T cell subsets	T025	C0080202
27259326	737	745	NK cells	T025	C0022688
27259326	749	765	peripheral blood	T031	C0229664
27259326	769	772	HCC	T191	C2239176
27259326	778	782	data	T078	C1511726
27259326	793	810	alpha-fetoprotein	T116,T123	C0002210
27259326	812	815	AFP	T116,T123	C0002210
27259326	817	823	levels	T080	C0441889
27259326	827	843	peripheral blood	T031	C0229664
27259326	863	875	up-regulated	T044	C0041904
27259326	879	882	HCC	T191	C2239176
27259326	883	891	patients	T101	C0030705
27259326	899	908	treatment	T061	C0087111
27259326	914	922	compared	T052	C1707455
27259326	928	935	healthy	T080	C3898900
27259326	936	942	people	T098	C0027361
27259326	947	954	reduced	T080	C0392756
27259326	961	965	TACE	T061	C3888803
27259326	980	984	AHCS	T061	C0010408
27259326	985	994	treatment	T061	C0087111
27259326	1034	1044	CD4+ cells	T025	C0039215
27259326	1049	1057	NK cells	T025	C0022688
27259326	1058	1067	decreased	T081	C0205216
27259326	1083	1093	CD8+ cells	T025	C0242629
27259326	1094	1103	increased	T081	C0205217
27259326	1118	1121	HCC	T191	C2239176
27259326	1122	1130	patients	T101	C0030705
27259326	1136	1144	compared	T052	C1707455
27259326	1150	1157	healthy	T080	C3898900
27259326	1158	1164	people	T098	C0027361
27259326	1172	1181	treatment	T061	C0087111
27259326	1187	1197	CD4+ cells	T025	C0039215
27259326	1199	1203	CD4+	T025	C0039215
27259326	1206	1210	CD8+	T025	C0242629
27259326	1211	1216	ratio	T081	C0456603
27259326	1222	1230	NK cells	T025	C0022688
27259326	1249	1258	increased	T081	C0205217
27259326	1262	1265	HCC	T191	C2239176
27259326	1266	1274	patients	T101	C0030705
27259326	1300	1310	CD8+ cells	T025	C0242629
27259326	1330	1339	decreased	T081	C0205216
27259326	1352	1356	TACE	T061	C3888803
27259326	1371	1375	AHCS	T061	C0010408
27259326	1376	1385	treatment	T061	C0087111
27259326	1413	1417	year	T079	C0439234
27259326	1418	1431	survival rate	T081	C0038954
27259326	1435	1438	HCC	T191	C2239176
27259326	1439	1447	patients	T101	C0030705
27259326	1477	1489	side effects	T046	C0879626
27259326	1511	1515	data	T078	C1511726
27259326	1530	1534	TACE	T061	C3888803
27259326	1549	1553	AHCS	T061	C0010408
27259326	1554	1563	treatment	T061	C0087111
27259326	1564	1572	improves	T033	C0184511
27259326	1573	1581	patients	T101	C0030705
27259326	1584	1597	immune system	T022	C0020962
27259326	1620	1629	effective	T080	C1704419
27259326	1630	1648	therapeutic method	T061	C0087111
27259326	1653	1656	HCC	T191	C2239176
27259326	1657	1665	patients	T101	C0030705